Medizone Intl. (fka MZEIQ)

[pennytradex]

Medizone International, Inc., is a research and development company engaged in developing its AsepticSure(TM) technology to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. The trial program has been expanded in final preparation for a hospital mock-up, intended to be followed by hospital beta testing. It is estimated hospitals deploying the AsepticSure(TM) system will save $6 to $7 for each $1 invested while preventing tens of thousands of hospital acquired infections.

Check the outstanding shares on this stock – Very Low - 186,292,795 as of Jul 31, 2008. It takes very little buying to really move this stock to the upside quickly since the float is so low.

Link to pink sheets quote - http://www.pinksheets.com/pink/quote/quote.jsp?symbol=mzei

Think in terms of this – number of hospitals, clinics, etc, times number of AsepticSure units sold. Big income for this small company with a small stock float. Massive increase in share price. 1,000%, 10,000%, 50,000%, it could be huge. Is 100,000% possible (that would be $130 per share verses 13 cents per share now).

StockGure Report on MZEI
http://www.stockguru.com/stockguru-spotlights-nobody-outperforms-our-picks/special-situation-report/

Some quotes pulled from some of the news releases – can be found on Yahoo

The Story of Hospital Acquired Infections on the Rise
The CDC maintains the National Nosocomial (HOSPITAL ACQUIRED) Infections Surveillance System database, although it does not flag nosocomial infections by hospital or differentiate between HAl staph aureus germs or CA strains linked to USA 300. Nationally, CDC estimates there were 1.7 million health care-associated infections resulting in 99,000 deaths in 2002. A recent CDC report estimated the annual costs of health care-associated infections to U.S. hospitals to be between $28 billion and $45 billion.

The media has identified hospital’s unwillingness to address hospital acquired infections as a “Culture of Resistance.

Generally, a shareholder will purchase a biotech stock and hold it. This Company is ready to market their product in the very short term. This represents an amazing opportunity.

If there was ever a time to buy a bio-tech … it is now and this is THE company.

Medizone International, Inc. announces that a third round of AsepticSure(TM) trials have begun at Innovation Park, Queen's University. Building on the results obtained during the first and second round of laboratory testing, this third round is being conducted to establish the precise protocols necessary in order to obtain maximum bactericidal action in combination with minimum turn-around times in keeping with normal hospital flow patterns. Simultaneously, a development prototype is being finalized in order to conduct a full room scale hospital mock up.

Link to Yahoo News and quote on MZEI - http://finance.yahoo.com/q?s=MZEI.OB

I believe once the AsepticSure(TM) technology is approved by the FDA this stock is going to really move to the upside. Do your own DD and check it out.

Full Disclosure - I am long this stock.